0.00
—
Close of 30 Oct 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Pathfinder Cell Therapy
Its shares trade under the ticker PFND. It has been listed since 22 September 1992.
Pathfinder Cell Therapy, Inc. is a development stage regenerative medicine company. The company is headquartered in Cambridge, Massachusetts. The firm is seeking to develop cell-based and related therapies for the treatment of a range of diseases and medical conditions characterized by organ-specific cell damage. The firm is engaged in developing cell-based therapy for the treatment of diabetes, renal disease, myocardial infarction and other diseases characterized by organ-specific cell damage. The firm has discovered a mammalian cell type, which is able to stimulate damaged tissues to regenerate without the Pathfinder Cells (PCs) themselves being incorporated into the new tissue. PCs have shown efficacy in approximately three different animal models of diabetes, cardiac ischemia and renal reperfusion injury. The firm has tested these models for PCs from both rat and human sources. As of September 30, 2015, the Company had no revenue generated.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 22 Sept 1992
- Employees
- 1
- Website
- pathfindercelltherapy.com ↗
Leadership
Pay as last reported
- Joerg GruberChairman of the Board, since 2007
- Dr. Richard FranklinPresident, Chief Executive Officer, Secretary, Director, since 2000$120,000
- John BensonChief Financial Officer, Treasurer$119,000
- Dr. John AlamIndependent Director
- Mr. John BrooksIndependent Director
- Zen ChuIndependent Director
- Mr. Brock ReeveIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Pathfinder Cell Therapy Inc has a technologically advanced and innovative approach in the field of cell therapy. It possesses a highly skilled team of scientists and researchers who are experts in their respective domains. The company has strong intellectual property rights and a diverse portfolio of patented cell therapy technologies. This helps in gaining a competitive advantage and attracting potential investors.
Weaknesses
- One of the weaknesses of Pathfinder Cell Therapy Inc is its current lack of a commercialized product in the market. This may impact its revenue generation capabilities and overall financial stability. Additionally, as a relatively new company, it may face challenges related to brand recognition and market penetration.
Opportunities
- The field of cell therapy is rapidly growing, presenting numerous opportunities for Pathfinder Cell Therapy Inc. The increasing prevalence of chronic diseases, coupled with the rising aging population, provides a large and growing market for cell therapy solutions. Moreover, the company can explore strategic partnerships with established pharmaceutical companies to drive research and development collaborations and accelerate the commercialization process.
Threats
- Pathfinder Cell Therapy Inc faces potential threats from both regulatory and competitive factors. The stringent regulatory requirements and approval processes for cell therapy products may result in delays and increased costs. Furthermore, the presence of established players in the market who have already commercialized cell therapy products poses a competitive threat, requiring the company to differentiate itself and prove the superiority of its technologies.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.